Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis

被引：0
作者：
Djillali Annane
Jean-Paul Mira
Lorraine B. Ware
Anthony C. Gordon
Charles J. Hinds
David C. Christiani
Jonathan Sevransky
Kathleen Barnes
Timothy G. Buchman
Patrick J. Heagerty
Robert Balshaw
Nadia Lesnikova
Karen de Nobrega
Hugh F. Wellman
Mauricio Neira
Alexandra D. J. Mancini
Keith R. Walley
James A. Russell
机构：
[1] Hopital R. Poincare,Service de Reanimation Medicale
[2] Université Paris Descartes,Sorbonne Paris Cité, Cochin Hotel
[3] Vanderbilt University School of Medicine,Dieu University Hospital Medical Intensive Care Unit, AP
[4] Imperial College London,HP
[5] Queen Mary University of London,Departments of Medicine and Pathology, Microbiology and Immunology
[6] Harvard Medical School and School of Public Health,Section of Anaesthetics, Pain Medicine, and Intensive Care, Charing Cross Hospital
[7] Emory University,Barts and The London School of Medicine
[8] Johns Hopkins University,Emory Center for Critical Care, Woodruff Health Sciences Center
[9] University of Washington,Division of Allergy and Clinical Immunology, Department of Medicine
[10] Syreon Corporation,Department of Biostatistics
[11] Formerly with Sirius Genomics Inc,Critical Care Research Laboratories, Centre for Heart Lung Innovation, St. Paul’s Hospital
[12] University of British Columbia,undefined
来源：
Annals of Intensive Care | / 8卷
关键词：
Drotrecogin alfa (activated); Activated protein C; Pharmacogenomics biomarker; Propensity score; Severe sepsis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 53 条
[1]  
Wang L(2011)Genomics and drug response N Engl J Med 364 1144-1153
[2]  
McLeod HL(2008)Genetic determinants of response to warfarin during initial anticoagulation N Engl J Med 358 999-1008
[3]  
Weinshilboum RM(2005)Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 2285-2293
[4]  
Schwarz UI(2001)Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-709
[5]  
Ritchie MD(2005)Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 353 1332-1341
[6]  
Bradford Y(2012)Drotrecogin alfa (activated) in adults with septic shock N Engl J Med 366 2055-2064
[7]  
Rieder MJ(2013)Recombinant human activated protein C for adults with septic shock: a randomized controlled trial Am J Respir Crit Care Med 187 1091-1097
[8]  
Reiner AP(2012)Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated) Ann Intensive Care 2 15-887
[9]  
Gage BF(2008)Vasopressin versus norepinephrine infusion in patients with septic shock N Engl J Med 358 877-434
[10]  
Bernard GR(2008)Drotrecogin alfa (activated): real-life use and outcomes for the UK Crit Care 12 R58-23
123456